Related Experiment Video
Updated: Nov 20, 2025
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma
Hiroaki Katagi1,2, Nozomu Takata3, Yuki Aoi4
1Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Background:
Diffuse intrinsic pontine glioma (DIPG) is associated with transcriptional dysregulation driven by H3K27 mutation. The super elongation complex (SEC) is required for transcriptional elongation through release of RNA polymerase II (Pol II). Inhibition of transcription elongation by SEC disruption can be an effective therapeutic strategy of H3K27M-mutant DIPG. Here, we tested the effect of pharmacological disruption of the SEC in H3K27M-mutant DIPG to advance understanding of the molecular mechanism and as a new therapeutic strategy for DIPG.
Methods:
Short hairpin RNAs (shRNAs) were used to suppress the expression of AF4/FMR2 4 (AFF4), a central SEC component, in H3K27M-mutant DIPG cells. A peptidomimetic lead compound KL-1 was used to disrupt a functional component of SEC. Cell viability assay, colony formation assay, and apoptosis assay were utilized to analyze the effects of KL-1 treatment. RNA- and ChIP-sequencing were used to determine the effects of KL-1 on gene expression and chromatin occupancy. We treated mice bearing H3K27M-mutant DIPG patient-derived xenografts (PDXs) with KL-1. Intracranial tumor growth was monitored by bioluminescence image and therapeutic response was evaluated by animal survival.
Results:
Depletion of AFF4 significantly reduced the cell growth of H3K27M-mutant DIPG. KL-1 increased genome-wide Pol II occupancy and suppressed transcription involving multiple cellular processes that promote cell proliferation and differentiation of DIPG. KL-1 treatment suppressed DIPG cell growth, increased apoptosis, and prolonged animal survival with H3K27M-mutant DIPG PDXs.
Conclusions:
SEC disruption by KL-1 increased therapeutic benefit in vitro and in vivo, supporting a potential therapeutic activity of KL-1 in H3K27M-mutant DIPG.
Insights
Pharmacological disruption of the super elongation complex (SEC) using KL-1 suppressed diffuse intrinsic pontine glioma (DIPG) cell growth. This SEC inhibition offers a promising therapeutic strategy for H3K27M-mutant DIPG.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Diffuse intrinsic pontine glioma (DIPG) is characterized by transcriptional dysregulation linked to H3K27 mutations.
- The super elongation complex (SEC) is crucial for transcriptional elongation, releasing RNA polymerase II (Pol II).
- Targeting SEC to inhibit transcription elongation presents a potential therapeutic avenue for H3K27M-mutant DIPG.
Purpose of the Study:
- To investigate the therapeutic potential of pharmacologically disrupting the SEC in H3K27M-mutant DIPG.
- To elucidate the molecular mechanisms underlying SEC inhibition in DIPG.
- To evaluate a novel therapeutic strategy for DIPG.
Main Methods:
- Suppressed AF4/FMR2 4 (AFF4), a key SEC component, using short hairpin RNAs (shRNAs).
- Utilized a peptidomimetic compound KL-1 to disrupt SEC function.
- Assessed cell viability, colony formation, and apoptosis; performed RNA- and ChIP-sequencing.
- Evaluated KL-1 efficacy in H3K27M-mutant DIPG patient-derived xenografts (PDXs) in mice.
Main Results:
- AFF4 depletion significantly inhibited H3K27M-mutant DIPG cell growth.
- KL-1 treatment enhanced genome-wide Pol II occupancy and suppressed transcription.
- KL-1 suppressed DIPG cell proliferation and differentiation, increased apoptosis, and prolonged survival in PDX models.
Conclusions:
- SEC disruption via KL-1 demonstrated therapeutic benefits both in vitro and in vivo.
- KL-1 shows potential as a therapeutic agent for H3K27M-mutant DIPG.
- This study supports SEC inhibition as a viable strategy for DIPG treatment.
